Clinical trial
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be…
NCT00435825 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00435825 |
|---|---|
| Title | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB). |
| Official title | A Randomized, Double-blind Study of the Effect of Treatment Duration and Dose of PEGASYS on HBeAg Seroconversion and Safety in Patients With HBeAg Positive Chronic Hepatitis B. |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis B, Chronic |
| Intervention type | Drug |
| Interventions | peginterferon alfa-2a [Pegasys] |
| Enrollment | 551 |
| Start date | Mar 1, 2007 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Feb 16, 2007 |
| Last update posted | Jun 25, 2013 |
| Countries | Australia, Brazil, China, France, Germany, Hong Kong, New Zealand, Russia, Singapore, South Korea, Taiwan, Thailand and 1 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: